Evenity (Romosozumab) Adolescent (12-17) Monitoring

Regulatory Status and the Off-Label Reality

Romosozumab carries an FDA indication limited to osteoporosis in postmenopausal women at high risk for fracture. No regulatory agency worldwide has approved it for patients under 18. Every adolescent prescription is off-label.

The drug works by inhibiting sclerostin, a glycoprotein secreted by osteocytes that normally suppresses the Wnt signaling pathway responsible for osteoblast activity. In the adult ARCH trial (N=4,093), romosozumab 210 mg monthly for 12 months followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months [1]. That result established efficacy in a postmenopausal population with a mean age of 74.3 years. Extrapolating those findings to a 14-year-old skeleton with open growth plates requires extreme caution.

The Endocrine Society's 2024 clinical practice guideline on pediatric bone health notes that "pharmacologic intervention for low bone density in children and adolescents should be considered only after optimizing calcium, vitamin D, weight-bearing activity, and treating the underlying condition" [2]. Romosozumab does not appear in any pediatric guideline as a recommended agent. The rare clinical scenarios where a specialist might consider it include osteogenesis imperfecta unresponsive to bisphosphonates, secondary osteoporosis from chronic glucocorticoid use, and skeletal fragility associated with oncologic treatment [3].

Baseline Assessment Before First Dose

A thorough pre-treatment workup separates defensible off-label prescribing from guesswork. The baseline evaluation should capture skeletal maturity, metabolic bone status, cardiovascular risk, and psychological wellbeing before the first injection.

Start with a DXA scan at the lumbar spine and total body less head (TBLH), the two sites endorsed by the International Society for Clinical Densitometry (ISCD) for pediatric patients [4]. Record Z-scores, not T-scores. A Z-score of <-2.0 adjusted for age, sex, and body size meets the ISCD definition of "low bone mineral density for chronological age" in children [4]. Obtain a left-hand bone-age radiograph and, if the patient is still growing, anteroposterior knee or wrist films to document physeal status.

Draw fasting serum calcium, phosphorus, 25-hydroxyvitamin D, intact PTH, P1NP (procollagen type I N-terminal propeptide), and CTX (C-terminal telopeptide). P1NP and CTX together give a formation-resorption snapshot. In healthy adolescents, P1NP levels during peak growth can exceed 200 mcg/L, several times higher than adult reference ranges [5]. Documenting these values at baseline prevents misinterpretation of treatment-related changes later.

Romosozumab carries a boxed warning for major adverse cardiovascular events (MACE). The ARCH trial reported a higher incidence of adjudicated cardiovascular serious adverse events (2.5%) compared with alendronate (1.9%) over the first 12 months [1]. Although adolescents generally have low baseline cardiovascular risk, any history of congenital heart disease, Kawasaki disease, familial hypercholesterolemia, or hypertension warrants cardiology clearance. Record resting blood pressure, a fasting lipid panel, and a focused family history for premature MACE.

Bone Biomarker Monitoring During Treatment

Serial bone-turnover markers are the earliest pharmacodynamic signal a clinician can track. They shift weeks before DXA changes become detectable.

In adult studies, romosozumab increased P1NP by approximately 145% from baseline within the first month of treatment, with levels peaking at month 1 and gradually declining toward baseline by month 9 [6]. CTX, the resorption marker, dropped by roughly 40% to 55% in the same period [6]. The net effect is a widening of the "anabolic window" where formation outpaces resorption. This window closes over time because of a physiologic feedback loop involving increased sclerostin-independent Wnt pathway regulation.

For an adolescent protocol, draw P1NP and CTX at baseline, month 3, month 6, month 9, and month 12. A failure of P1NP to rise by at least 50% from baseline by month 3 should prompt a medication adherence review and reassessment of calcium/vitamin D status. A paradoxical rise in CTX during treatment may signal non-adherence or an intercurrent metabolic disturbance such as hyperparathyroidism.

The 2020 American Association of Clinical Endocrinology (AACE) guidelines for postmenopausal osteoporosis state that "bone turnover markers can be used to monitor medication adherence and efficacy, with significant changes expected within 3 to 6 months of treatment initiation" [7]. While this language targets adult women, the pharmacokinetic rationale applies to any patient receiving the drug.

DXA and Imaging Schedule

DXA provides the structural outcome data that biomarkers cannot. In a still-growing adolescent, the interpretation is more complex than in an adult.

Repeat DXA at 6 months and 12 months during treatment. Use the same scanner and the same technologist when possible. The ISCD recommends a minimum interval of 6 months for repeat DXA in pediatric patients receiving bone-active therapy [4]. The expected gain in lumbar spine BMD with romosozumab in adults averages 13.3% at 12 months, based on data from the FRAME trial (N=7,180) [8]. Adolescents may show different magnitudes of response because of higher baseline bone turnover and ongoing skeletal modeling.

Report Z-scores adjusted for height-age rather than chronological age in any adolescent who falls below the 3rd percentile for height. The ISCD 2019 position statement specifies that "height-adjusted Z-scores should be used when short stature is present to avoid overdiagnosis of low bone density" [4].

Growth-plate imaging deserves its own cadence. Obtain anteroposterior wrist or knee radiographs at baseline, 6 months, and 12 months. Sclerostin is expressed in hypertrophic chondrocytes at the physis [9]. Animal models of sclerostin knockout show increased trabecular bone volume but also altered endochondral ossification patterns [9]. No human pediatric data exist to confirm or refute premature physeal closure with romosozumab, but the biological plausibility demands surveillance. If radiographs show accelerated narrowing of the physis compared with expected skeletal maturity, treatment should be paused and a pediatric endocrinologist consulted.

Cardiovascular Monitoring in a Low-Risk Population

The boxed warning on romosozumab's FDA label states: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death" [10]. This warning emerged from the ARCH trial, where the romosozumab-to-alendronate arm had 50 confirmed MACE events over 12 months versus 38 in the alendronate-to-alendronate arm [1].

Adolescents without pre-existing cardiovascular conditions have a low absolute risk. The concern is not zero, though. An adolescent with familial hypercholesterolemia might have LDL levels exceeding 190 mg/dL [11]. A patient on chronic corticosteroids may have metabolic syndrome features. And any patient with a history of Kawasaki disease could have coronary artery aneurysms that alter baseline risk.

Measure blood pressure at every monthly injection visit. Obtain a fasting lipid panel at baseline and at month 6. Any new-onset chest pain, exertional dyspnea, or neurological symptoms should trigger immediate evaluation. The threshold for pausing treatment and pursuing cardiology workup should be lower in an off-label pediatric patient than it would be in the indicated adult population.

Growth-Velocity Tracking

Romosozumab's mechanism targets the same Wnt pathway that governs longitudinal bone growth. Monitoring height velocity is not optional.

Record standing height at every monthly visit using a stadiometer calibrated to the nearest 0.1 cm. Calculate annualized growth velocity using measurements at least 3 months apart to reduce measurement error. Normal mid-pubertal growth velocity ranges from 7 to 12 cm/year in boys and 6 to 10 cm/year in girls [12]. A deceleration of more than 2 cm/year from the patient's own pre-treatment trajectory, after adjusting for expected pubertal stage, warrants investigation.

Cross-reference height velocity with bone-age progression. If bone age advances more than 1.5 years relative to chronological age over the treatment course, the drug may be accelerating skeletal maturation. This pattern would compress the remaining growth window, potentially reducing final adult height. In such cases, the treating team should weigh the fracture-prevention benefit against the growth cost.

Tanner staging at baseline and every 6 months provides a hormonal context for growth changes. A shift in pubertal stage may independently alter bone biomarkers and growth velocity, complicating attribution of changes to the drug itself.

Mental-Health Monitoring

Chronic injectable medications, monthly clinic visits, and the psychological weight of a rare skeletal diagnosis create mental-health risks that adult monitoring protocols rarely address. Adolescents are not small adults in this regard.

Administer the Patient Health Questionnaire for Adolescents (PHQ-A) at baseline and at each quarterly biomarker draw (months 3, 6, 9, and 12). The PHQ-A is validated for screening depression in the 12-to-17 age range [13]. A score of 10 or higher warrants referral to a mental-health provider.

Ask about injection anxiety at each visit. Needle phobia affects approximately 20% to 30% of adolescents [14]. Romosozumab is administered as two separate 105 mg subcutaneous injections per dose, meaning the patient receives two needle sticks monthly. Topical lidocaine-prilocaine cream applied 30 to 60 minutes before injection, distraction techniques, and allowing the adolescent to choose the injection site (abdomen, thigh, or upper arm) may improve adherence.

Screen for disordered eating behaviors, particularly in adolescents whose skeletal fragility is linked to low body weight, female athlete triad, or relative energy deficiency in sport (RED-S). The 2023 IOC consensus on RED-S identifies low bone mineral density as a hallmark feature [15]. Treating the bone without addressing the energy deficit is treating the symptom, not the disease.

Post-Treatment Transition Planning

Romosozumab's anabolic gains erode rapidly without sequential antiresorptive therapy. In the FRAME extension, patients who received placebo after 12 months of romosozumab lost roughly half of their BMD gains within the following year [8]. A transition plan should be established before the first dose, not after the twelfth.

For adults, the standard sequence is romosozumab for 12 months followed by a bisphosphonate (alendronate or zoledronic acid) or denosumab. In adolescents, the choice of antiresorptive requires additional thought. Bisphosphonates incorporate into the bone matrix and can persist for years, potentially affecting a future pregnancy decades later [16]. Denosumab carries a rebound vertebral fracture risk upon discontinuation that is well-documented in adults [17]. Neither option is ideal. The treating team should discuss these trade-offs with the patient and family before starting romosozumab.

After completing the 12-month course, continue DXA annually for at least 2 years. Continue bone-turnover markers every 6 months for the first year post-treatment to confirm that BMD gains are being maintained by the sequential agent. If the patient is still growing, continue growth-plate imaging and height-velocity tracking until physeal closure is confirmed.

Building the Monitoring Calendar

Consolidating these requirements into a single schedule reduces missed assessments and clinic-visit burden. A practical calendar looks like this.

Before dose 1: DXA (lumbar spine + TBLH), bone age, growth-plate films, P1NP, CTX, calcium, phosphorus, 25(OH)D, PTH, fasting lipids, blood pressure, Tanner stage, PHQ-A, height.

Monthly (doses 1 through 12): Blood pressure, height, injection-site assessment, injection-anxiety screen, adverse-event review.

Quarterly (months 3, 6, 9, 12): P1NP, CTX, PHQ-A, and at months 6 and 12 add DXA and growth-plate films. Month 6 also includes a repeat fasting lipid panel.

Post-treatment (months 18, 24): DXA, P1NP, CTX, growth-plate films (if physes still open), height velocity review.

This cadence produces 12 monthly touchpoints, 4 biomarker draws, 2 to 3 imaging sessions, and 4 mental-health screens across the treatment year. Each visit takes 15 to 20 minutes beyond the injection itself if labs are pre-drawn.

The absence of pediatric trial data for romosozumab means every adolescent patient is, in effect, an N-of-1 experiment. Structured monitoring does not eliminate uncertainty, but it compresses the interval between a developing problem and its detection. A 3-month biomarker lag is recoverable. A 12-month missed cardiovascular signal is not.